高危上尿路尿路上皮癌根治性肾输尿管切除术后肿瘤学监测
基于8个欧洲转诊中心前瞻性数据库的1378例高危上尿路尿路上皮癌患者,评估根治性肾输尿管切除术后按EAU指南监测的膀胱复发和非膀胱复发风险,并分析无既往膀胱癌史患者按年龄分层是否可停止监测。中位随访4年,5年时膀胱复发风险10%,2年时非膀胱复发风险无既往膀胱癌史42% vs 有既往膀胱癌史47%。作者建议4年前每半年影像监测,4年后每年膀胱镜监测,部分无既往膀胱癌史者可停止监测。
要点
- 5年时膀胱复发风险为10%,4年时为13%。
- 2年时非膀胱复发风险无既往膀胱癌史42% vs 有既往膀胱癌史47%。
- 无既往膀胱癌史者中,<60岁应继续膀胱镜和影像监测超过10年,70-79岁仅继续影像监测超过10年,>80岁可因其他原因死亡风险增加而停止监测。
核心结论
- 作者建议将影像监测频率加强至术后第4年每半年一次,4年后复发风险几乎减半。
- 鉴于术后4年和5年复发风险相似,膀胱镜可从第4年起每年一次。
- 部分无既往膀胱癌史者可停止肿瘤学监测。
研究设计与样本
- 研究为基于8个欧洲转诊中心前瞻性维护数据库的队列分析,纳入1378例按EAU指南定义的高危上尿路尿路上皮癌患者。
- 监测方案按EAU指南基于膀胱镜和横断面影像进行。
- 采用调整Weibull回归识别其他原因死亡风险超过复发风险的时间点。
主要发现
- 中位随访4年,有既往膀胱癌史427例,无既往膀胱癌史951例。
- 5年时膀胱复发风险10%,4年时膀胱复发风险13%。
- 2年时非膀胱复发风险无既往膀胱癌史42% vs 有既往膀胱癌史47%,4年时非膀胱复发风险23%。
- 无既往膀胱癌史者中,<60岁应继续膀胱镜和影像监测超过术后10年,70-79岁仅继续影像监测超过10年,>80岁可因其他原因死亡风险增加而停止肿瘤学监测。
关键数值与推荐
- 5年时膀胱复发风险10%(原文建议此后膀胱镜每半年一次的时间点)。
- 4年时膀胱复发风险13%。
- 2年时非膀胱复发风险无既往膀胱癌史42% vs 有既往膀胱癌史47%(原文建议此后影像每半年一次的时间点)。
- 4年时非膀胱复发风险23%。
- 无既往膀胱癌史者中,<60岁应继续膀胱镜和影像监测超过术后10年,70-79岁仅继续影像监测超过10年,>80岁可停止肿瘤学监测。
临床怎么用
- 作者建议将影像监测频率加强至术后第4年每半年一次,4年后复发风险几乎减半。
- 作者建议膀胱镜可从第4年起每年一次,因术后4年和5年复发风险相似。
- 作者认为部分无既往膀胱癌史者可停止肿瘤学监测。
局限性
- 局限性包括患者接受治疗和监测的时间跨度相对较长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The appropriate surveillance protocol after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) is still poorly addressed. OBJECTIVE: To evaluate the appropriate intensity and duration of oncologic surveillance following RNU, according to a prior history of bladder cancer (BCa). DESIGN, SETTING, AND PARTICIPANTS: We identified 1378 high-risk UTUC patients, according to the European Association of Urology (EAU) guidelines, from a prospectively maintained database involving eight European referral centers. Surveillance protocol was based on cystoscopies and cross-sectional imaging, as per the EAU guidelines. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: First, we evaluated the noncumulative risk of bladder and other-site recurrences (including distant metastasis and locoregional relapse) against the follow-up time points, as suggested by the current EAU guidelines. Second, in an effort to identify the time points when the risk of other-cause mortality (OCM) exceeded that of recurrence and follow-up might be discontinued, we relied on adjusted Weibull regression. RESULTS AND LIMITATIONS: The median follow-up was 4 yr. A total of 427 and 951 patients with and without a prior BCa history, respectively, were considered. At 5-yr, the time point after which cystoscopies should be performed semiannually, the bladder recurrence risk was 10%; at 4 yr, the bladder recurrence risk was 13%. At 2 yr, the time point after which imaging should be obtained semiannually, the nonbladder recurrence risk was 42% in case of nonprior BCa and 47% in case of prior BCa; at 4 yr, the nonbladder recurrence risk was 23%. Among patients without a prior BCa history, individuals younger than 60 yr should continue both cystoscopies and imaging beyond 10 yr from RNU, 70-79-yr-old patients should continue only imaging beyond 10 yr, while patients older than 80 yr might discontinue oncologic surveillance because of an increased risk of OCM. Limitations include the fact that patients were treated and surveilled over a relatively long period of time. CONCLUSIONS: We suggest intensifying the frequency of imaging to semiannual till the 4th year after RNU, the time point after which the risk of recurrence was almost halved. Cystoscopies could be obtained annually from the 4th year given a similar risk of recurrence at 4 and 5 yr after RNU. Oncologic surveillance could be discontinued in some cases in the absence of a prior BCa history. PATIENT SUMMARY: In this study, we propose a revision of the current guidelines regarding surveillance protocols following radical nephroureterectomy. We also evaluated whether oncologic surveillance for high-risk upper tract urothelial carcinoma could be discontinued and, if so, in what circumstances.
引用
- Martini A, Lonati C, Nocera L, et al. Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2022. PMID: 35504834. doi:10.1016/j.euo.2022.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。